BETA Stock Overview
Develops, manufactures, and sells anti-cancer drugs in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Beta Drugs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,929.95 |
| 52 Week High | ₹2,326.00 |
| 52 Week Low | ₹1,060.05 |
| Beta | 0.53 |
| 1 Month Change | -3.42% |
| 3 Month Change | -10.66% |
| 1 Year Change | 39.92% |
| 3 Year Change | 231.98% |
| 5 Year Change | 2,824.17% |
| Change since IPO | 1,722.43% |
Recent News & Updates
Recent updates
Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge
Nov 08
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Aug 30Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%
Aug 30Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%
Dec 23Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Dec 11These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Jul 29Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching
Jun 17Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today
Feb 21Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
Dec 20With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting
Nov 21These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Sep 02Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
May 20Is Beta Drugs (NSE:BETA) A Risky Investment?
Jan 29Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Dec 25Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)
Nov 20
Shareholder Returns
| BETA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.0% | 4.4% | 3.8% |
| 1Y | 39.9% | 18.0% | 5.9% |
Return vs Industry: BETA exceeded the Indian Pharmaceuticals industry which returned 18% over the past year.
Return vs Market: BETA exceeded the Indian Market which returned 5.9% over the past year.
Price Volatility
| BETA volatility | |
|---|---|
| BETA Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: BETA's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: BETA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 371 | Rahul Batra | betadrugslimited.com |
Beta Drugs Limited develops, manufactures, and sells anti-cancer drugs in India. The company offers oncology products in the areas of breast, lung, head and neck, colorectal, ovarian, gastric, testicular, renal, and prostate cancer, as well as brain tumor, leukemia, lymphoma, myeloma, and supportive cancer; and dermatology products. It also develops active pharmaceutical ingredients.
Beta Drugs Limited Fundamentals Summary
| BETA fundamental statistics | |
|---|---|
| Market cap | ₹19.33b |
| Earnings (TTM) | ₹410.00m |
| Revenue (TTM) | ₹3.35b |
45.3x
P/E Ratio5.5x
P/S RatioIs BETA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BETA income statement (TTM) | |
|---|---|
| Revenue | ₹3.35b |
| Cost of Revenue | ₹2.01b |
| Gross Profit | ₹1.34b |
| Other Expenses | ₹925.54m |
| Earnings | ₹410.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 42.65 |
| Gross Margin | 39.90% |
| Net Profit Margin | 12.25% |
| Debt/Equity Ratio | 10.5% |
How did BETA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/05 15:19 |
| End of Day Share Price | 2025/02/05 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beta Drugs Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.